Evidence map›Paper›PMID 42626954›Full record

ArticleJournal of clinical microbiology2026

Rapid MALDI-TOF MS antimicrobial susceptibility testing with the MBT FAST assay.

Evgeny A Idelevich, Kathrin Alpers, Michael Buhl, Oliver Drews, Stephen P Kidd, Markus Kostrzewa, Nathan Moore, Ilka D Nix, Boris Oberheitmann, Fatima Pereira and 9 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Evgeny A IdelevichFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.ORCID 0009-0009-4207-5290
Kathrin AlpersBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Michael BuhlInstitute of Clinical Microbiology, Infectious Diseases and Infection Control, Paracelsus Medical University, Klinikum Nürnberg, Nürnberg, Germany.
Oliver DrewsBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Stephen P KiddBasingstoke and North Hampshire Hospital, Infection Sciences Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom.
Markus KostrzewaBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Nathan MooreBasingstoke and North Hampshire Hospital, Infection Sciences Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom.
Ilka D NixBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Boris OberheitmannBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Fatima PereiraBasingstoke and North Hampshire Hospital, Infection Sciences Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom.
Arthur PranadaDivision of Medical Microbiology, MVZ Dr. Eberhard & Partner Dortmund, Dortmund, Germany.
Ines ScholzDepartment of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Christian WalterDepartment of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0009-0006-7982-3430
Katrin SparbierBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Martin SpülerBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Jörg SteinmannInstitute of Clinical Microbiology, Infectious Diseases and Infection Control, Paracelsus Medical University, Klinikum Nürnberg, Nürnberg, Germany.
Jaqueline WeferlingBruker Daltonics GmbH & Co. KG, Bremen, Germany.
Stefan ZimmermannDepartment of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-5601-7934
Karsten BeckerFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.ORCID 0000-0002-6391-1341

Funding

European Regional Development Fund GHS-20-0010German Federal Ministry of Education and Research 16GW0149KGerman Federal Ministry of Education and Research 16GW0150
6 · The paper itself

Abstract

The rise of multidrug-resistant microorganisms highlights the need for rapid antimicrobial susceptibility testing (AST) to guide early and effective therapy. This study evaluated a novel MALDI-TOF MS-based assay (MBT FAST, Bruker, Germany), which employs the direct-on-target microdroplet growth assay (DOT-MGA) for phenotypic AST. A total of 243 IMPORTANCE: Standard antimicrobial susceptibility testing requires prolonged incubation, delaying targeted treatment and de-escalation. This study evaluated MBT FAST, a MALDI-TOF MS-based assay that measures bacterial growth directly on the MALDI target plate in the presence of antibiotics. In a diverse collection of

Indexed as

Anti-Bacterial AgentsEnterobacteriaceaeSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationHumansMicrobial Sensitivity TestsTime FactorsAnti-Bacterial Agentsantibioticsdirect-on-target microdroplet growth assayMALDI-TOF MSrapid antimicrobial susceptibility testing

Identifiers

PMID42626954
PMCPMC13556253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.